Green Square Capital LLC boosted its stake in shares of Allergan PLC. (NYSE:AGN) by 3.6% during the first quarter, Holdings Channel reports. The institutional investor owned 5,916 shares of the company’s stock after buying an additional 203 shares during the period. Green Square Capital LLC’s holdings in Allergan PLC. were worth $1,413,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in AGN. Veritas Asset Management LLP purchased a new position in Allergan PLC. during the first quarter valued at $761,339,000. Edgewood Management LLC raised its position in Allergan PLC. by 7.0% in the first quarter. Edgewood Management LLC now owns 2,704,211 shares of the company’s stock valued at $646,090,000 after buying an additional 178,055 shares in the last quarter. Epoch Investment Partners Inc. raised its position in Allergan PLC. by 3.8% in the first quarter. Epoch Investment Partners Inc. now owns 2,013,415 shares of the company’s stock valued at $481,045,000 after buying an additional 73,081 shares in the last quarter. UBS Asset Management Americas Inc. raised its position in Allergan PLC. by 0.3% in the first quarter. UBS Asset Management Americas Inc. now owns 1,995,281 shares of the company’s stock valued at $476,713,000 after buying an additional 5,042 shares in the last quarter. Finally, Blue Ridge Capital L.L.C. raised its position in Allergan PLC. by 24.1% in the first quarter. Blue Ridge Capital L.L.C. now owns 1,909,900 shares of the company’s stock valued at $456,313,000 after buying an additional 370,400 shares in the last quarter. 84.77% of the stock is currently owned by institutional investors and hedge funds.

Allergan PLC. (AGN) traded up 1.5144% during midday trading on Tuesday, reaching $244.8731. The company’s stock had a trading volume of 654,894 shares. Allergan PLC. has a 52 week low of $184.50 and a 52 week high of $256.80. The stock has a 50 day moving average of $245.21 and a 200 day moving average of $237.12. The firm has a market capitalization of $82.24 billion, a PE ratio of 7.6299 and a beta of 1.16.

Allergan PLC. (NYSE:AGN) last announced its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, beating the consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.25% and a net margin of 79.17%. The firm had revenue of $4.01 billion during the quarter, compared to the consensus estimate of $3.95 billion. During the same quarter in the prior year, the company earned $3.35 EPS. The firm’s revenue for the quarter was up 8.8% compared to the same quarter last year. On average, equities research analysts predict that Allergan PLC. will post $16.21 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Friday, August 18th will be paid a dividend of $0.70 per share. The ex-dividend date is Wednesday, August 16th. This represents a $2.80 annualized dividend and a yield of 1.16%. Allergan PLC.’s payout ratio is 9.95%.

TRADEMARK VIOLATION NOTICE: This article was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.thecerbatgem.com/2017/08/08/allergan-plc-nyseagn-shares-bought-by-green-square-capital-llc.html.

Several equities analysts have recently weighed in on AGN shares. Citigroup Inc. reaffirmed a “focus list” rating and issued a $261.27 price objective (up from $184.50) on shares of Allergan PLC. in a research note on Friday, April 21st. Deutsche Bank AG reaffirmed a “buy” rating and issued a $273.00 price objective (up from $265.00) on shares of Allergan PLC. in a research note on Monday, July 17th. Goldman Sachs Group, Inc. (The) lowered Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 price objective on the stock. in a research note on Wednesday, May 10th. Royal Bank Of Canada lifted their price objective on Allergan PLC. from $279.00 to $284.00 and gave the company an “outperform” rating in a research note on Wednesday, May 10th. Finally, Credit Suisse Group set a $288.00 price objective on Allergan PLC. and gave the company a “buy” rating in a research note on Saturday. Seven investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Allergan PLC. currently has a consensus rating of “Buy” and an average price target of $274.14.

In related news, Director Nesli Basgoz sold 1,889 shares of the stock in a transaction that occurred on Thursday, May 18th. The stock was sold at an average price of $220.45, for a total transaction of $416,430.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.36% of the stock is owned by corporate insiders.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.